DOI: 10.32364/2618-8430-2019-2-2-135-138

Managing invasive cervical cancer in pregnancy

Yu.G.Payanidi¹, E.I. Borovkova², Yu.E. Dobrohotova², A.M. Arutunyan<sup>2

1</sup> Blokhin Cancer Research Center, Moscow, Russian Federation
² Pirogov Russian National Research Medical University, Moscow, Russian Federation

Cervical cancer is one of the most common cancers diagnosed during the pregnancy. Its incidence is 1.5 cases per 10 000 births. During gestation, cancer staging and treatment should meet current standards and be similar to the treatment strategy in non-pregnant women. Key treatment approaches to the invasive cervical cancer are surgery and pharmacotherapy (chemotherapy). Treatment strategy is determined by the gestational period when the condition was diagnosed, cancer stage, tumor size, and regional lymph nodes involvement. When diagnosed up to 20 weeks, treatment approach choice depends on the decision of whether to proceed a pregnancy or not. In cervix cancer stage ІА2 and stage IB1 and in tumor size less than 2 cm, conization and lymph node dissection are recommended. In case of lymph node involvement in a women who is pregnant less than 22 weeks, abortion is recommended. If a woman decides to proceed her pregnancy, neoadjuvant chemotherapy is recommended. At 22 weeks pregnancy, lymphadenectomy is challenging; cancer staging is performed by histological examination. Standard chemotherapeutic strategy involves cisplatin monotherapy or cisplatin plus paclitaxel.

Keywords: pregnancy, cervical cancer, clinical guidelines, conization, neoadjuvant chemotherapy.
For citation: Payanidi Yu.G., Borovkova E.I., Dobrohotova Yu.E., Arutunyan A.M. Managing invasive cervical cancer in pregnancy. Russian Journal of Woman and Child Health. 2019;2(2):135–138.